5-methyl-5-isopropyl-1,3-dioxane | 5702-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 5-methyl-5-isopropyl-1,3-dioxane
• 英文别名: 5-isopropyl-5-methyl-[1,3]dioxane；5-Isopropyl-5-methyl-1,3-dioxan；5-Methyl-5-isopropyl-1,3-dioxan；5-Methyl-5-propan-2-yl-1,3-dioxane
• CAS: 5702-52-3
• 化学式: C₈H₁₆O₂
• 分子量: 144.214
• InChiKey: JPSOUMPDWNDZMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methyl-5-isopropyl-1,3-dioxane 、 双(2-甲基丙氧基)-(2-甲基丙基)硼烷 在 zinc(II) chloride 作用下， 反应 2.0h， 生成
  参考文献：
  名称：

  Kuznetsov; Tereschenko; Gren', Russian Journal of General Chemistry, 1996, vol. 66, # 2, p. 263 - 265

  摘要：

  DOI：

文献信息

• 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE
  申请人：Suzuki Shinji

  公开号：US20120258961A1

  公开（公告）日：2012-10-11

  The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , ring A, Y and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种用于治疗由淀粉样蛋白β的产生、分泌或沉积引起的疾病的药物，例如，以下式(I)的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、环A、Y和点线在规范中定义，其药学上可接受的盐或溶剂化物。
• MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：Gilead Sciences, Inc.

  公开号：EP2861604B1

  公开（公告）日：2017-03-01
• C4-SPIRO-PYRROLIDINE ANTIVIRALS
  申请人：Or Yat Sun

  公开号：US20090022689A1

  公开（公告）日：2009-01-22

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.
• 6,7-UNSATURATED-7-CARBAMOYL SUBSTITUTED MORPHINAN DERIVATIVE
  申请人：INAGAKI Masanao

  公开号：US20120135978A1

  公开（公告）日：2012-05-31

  A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R 1 and R 2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R 3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R 4 is hydrogen or lower alkyl, R 5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably salt, or a solvate thereof is provided.